Drug-pricing program improved prostate cancer treatment adherence
Patients from socially vulnerable areas were more likely to stick with oral medications when treated at a hospital participating in 340B program
2024-03-20
(Press-News.org) ANN ARBOR, Michigan — Prostate cancer patients receiving care at hospitals that are part of a special drug-pricing program were more likely to stick to their prescription drug therapy than patients at other hospitals, according to a study from researchers at the University of Michigan’s Rogel Cancer Center and Institute for Healthcare Policy and Innovation.
The 340B Drug Pricing Program is a federal program that requires the pharmaceutical industry to provide a discount on the cost of drugs to participating hospitals who serve a disproportionate number of Medicare and Medicaid patients. The program was started to enable hospitals to stretch scarce resources, reach more patients and provide more comprehensive services.
“In the field of advanced prostate cancer, there’s been a paradigm shift to using newer targeted oral treatments. But these drugs are expensive, and cost can limit access to these drugs, particularly among those who are socioeconomically disadvantaged. We wanted to see if the 340B program could help mitigate this disparity,” said study first author Kassem Faraj, M.D., a urologic oncology fellow at Michigan Medicine.
The team looked back at a 20% sample of Medicare beneficiaries diagnosed with advanced prostate cancer and assessed who was treated with these targeted therapies at a hospital-based program. They identified 2,237 men treated at 340B-participating hospitals and 1,100 treated at non-participating hospitals.
They then looked at the social vulnerability index, a measure developed by the U.S. Centers for Disease Control and Prevention that characterizes socioeconomic, racial and household characteristics at the community-level. They found that patients from areas with greater social vulnerability were less likely to use the oral drugs. There was no difference in use between 340B and non-340B hospitals.
However, patients receiving treatment at 340B hospitals were more likely to continue treatment. The researchers saw that in non-340B hospitals, as social vulnerability increased, adherence dropped. But in 340B hospitals, adherence remained flat regardless of social vulnerability. Results were published in Cancer.
“There are many reasons why adherence to these drugs can drop. We suspect that 340B hospitals potentially have some resources or mechanisms that are helping these vulnerable patients maintain adherence,” Faraj said. This could include medication management programs or financial help for out-of-pocket drug costs.
“While 340B participation didn’t increase the number of patients using this therapy, it was associated with better treatment adherence among patients from socially vulnerable areas,” Faraj said.
Additional authors: Samuel R. Kaufman, Mary Oerline, Lindsey Herrel, Avinash Maganty, Megan E.V. Caram, Vahakn B. Shahinian, Brent K. Hollenbeck
Funding for this work is from National Cancer Institute grants T32 CA180984, R01 CA275993, R01 CA269367.
Disclosure: Michigan Medicine participates in the 340B program. Learn more about how the hospital provides community support.
Paper cited: “The 340B Program and oral specialty drugs for advanced prostate cancer,” Cancer. DOI: 10.1002/cncr.35262
Resources:
University of Michigan Rogel Cancer Center, www.rogelcancercenter.org
University of Michigan Institute for Healthcare Policy and Innovation, www.ihpi.umich.edu
Michigan Medicine Cancer AnswerLine, 800-865-1125
# # #
END
ELSE PRESS RELEASES FROM THIS DATE:
2024-03-20
Embargoed for release: Wednesday, March 20, 5:00 PM ET
Key points:
In a study of 4.3 million pregnant women and their children, prenatal exposure to topiramate, an antiseizure medication used to treat epilepsy, bipolar disorder, and migraines, was not associated with additional risk of the children developing autism spectrum disorder (ASD).
Consistent with previous research, the study also found that prenatal exposure to valproate and lamotrigine—two other antiseizure medications—were associated with ...
2024-03-20
An investigational gene therapy for a rare neurodegenerative disease that begins in early childhood, known as giant axonal neuropathy (GAN), was well tolerated and showed signs of therapeutic benefit in a clinical trial led by the National Institutes of Health (NIH). Currently, there is no treatment for GAN and the disease is usually fatal by 30 years of age. Fourteen children with GAN, ages 6 to 14 years, were treated with gene transfer therapy at the NIH Clinical Center and then followed for about six years to assess safety. Results ...
2024-03-20
Lithium metal batteries (LMBs) can provide nearly 10 times higher energy density compared to the present Lithium-ion batteries (LIBs) and hence are identified as one of the potential future storage systems. However, LMBs pose certain safety concerns and cannot be used for fast-charging applications. Uncontrolled dendrite formation, leading to excessive heating and battery short circuit is one of the critical challenges of its advancement.
Researchers have previously attempted to address the safety concerns in LMBs but with methods that were laboursome and money/time intensive. T. N. Narayanan’s lab at the Tata Institute ...
2024-03-20
IRVINE, CA, March 20, 2024 --The Pediatric Cancer Research Foundation (PCRF), a nonprofit focused on transforming pediatric cancer care by funding research breakthroughs, today announced the expansion of its leadership team. Executive Director Jeri Wilson, who has led the organization for 12 years, will step into the newly created role of Vice President of Development, Principal Gifts. Danielle Fragalla, a known nonprofit leader in California, will become Chief Executive Officer.
In the 12 years Ms. Wilson has led the Foundation, it has grown from a grassroots ...
2024-03-20
“These results suggest strong potential for clinical use of the assay in ctDNA monitoring of solid tumor cancers.”
BUFFALO, NY- March 20, 2024 – A new research paper was published in Oncotarget's Volume 15 on March 14, 2024, entitled, “Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay.”
In this new study, researchers Josette Northcott, Gabor Bartha, Jason Harris, Conan Li, Fabio C.P. Navarro, Rachel Marty Pyke, Manqing Hong, Qi Zhang, Shuyuan Ma, Tina X. Chen, Janet Lai, Nitin Udar, Juan-Sebastian Saldivar, Erin Ayash, ...
2024-03-20
The turbulent motion of a tumbling river or the outflow from a jet engine is chaotic: that is, it contains no obvious pattern.
But according to a new study, regular patterns can emerge from the turbulent motion of fluids. What you need is an intriguing property called “odd viscosity” that arises under certain conditions, such as when the particles in the fluid all spin in the same direction. Though it’s a specialized circumstance, there are many contexts in nature where a version of this effect may exist, such as in the ...
2024-03-20
COLUMBUS, Ohio — Treating anxiety and depression significantly reduced emergency room visits and rehospitalizations among people with heart disease, according to a study by researchers at The Ohio State University Wexner Medical Center.
“For patients hospitalized for coronary artery disease or heart failure and who had diagnoses of anxiety or depression, treatment with psychotherapy, medication or both was associated with as much as a 75% reduction in hospitalizations or emergency room visits. In some cases, there was a reduction in death,” said lead study author Philip Binkley, MD, executive ...
2024-03-20
A study led by University of Oklahoma researchers has been selected for a 2023 best paper award in the Advanced Formation Evaluation technical program theme from the Unconventional Resources Technology Conference.
The study examined how clay and kerogen, two different components within rocks, respond to nuclear magnetic resonance, or NMR, a technique used to assess the amount of fluids within rocks. Many fluids found within rocks contain hydrogen, and knowing whether and how much hydrogen is available in the subsurface is an important facet of oil and gas exploration. Researchers found that higher NMR frequencies improved data acquisition efficiency.
As a result of this study, a ...
2024-03-20
“This discovery unveils a potential novel molecular target for therapeutic strategies against hepatic steatosis during the aging process [...]”
BUFFALO, NY- March 20, 2024 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 5, entitled, “FoxO6-mediated ApoC3 upregulation promotes hepatic steatosis and hyperlipidemia in aged rats fed a high-fat diet.”
FoxO6, an identified factor, induces hyperlipidemia and hepatic steatosis during aging by activating hepatic ...
2024-03-20
Dr. Cochav Elkayam-Levy, of the Hebrew University of Jerusalem awarded the Israel Prize in the field of Solidarity (Arvut Hadadit) for her tireless work to raise awareness and acknowledgement to the crimes committed by Hamas on and following October 7th against Israeli women, children, men and families. Elkayam-Levy established the “Civil Commission on October 7th Crimes by Hamas against Women and Children”, aimed at giving voice to the victims and their families and raising awareness of the concerning developments in war crimes against women, children, men and families on and after October 7th and raising support for this cause.
Dr. Cochav Elkayam-Levy: ...
LAST 30 PRESS RELEASES:
[Press-News.org] Drug-pricing program improved prostate cancer treatment adherence
Patients from socially vulnerable areas were more likely to stick with oral medications when treated at a hospital participating in 340B program
